Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma

Bone Marrow Transplantation

Volumn 43, Issue 2, 2009, Pages 169-177

  Drobyski, W R ^a   Hari, P ^a   Keever Taylor, C ^a   Komorowski, R ^a   Grossman, W ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ALEMTUZUMAB; BORTEZOMIB; BUDESONIDE; BUSULFAN; CARMUSTINE; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DACLIZUMAB; DEXAMETHASONE; DOXORUBICIN; ETANERCEPT; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; IMMUNOGLOBULIN; INFLIXIMAB; MELPHALAN; METHOTREXATE; OCTREOTIDE; PREDNISONE; RITUXIMAB; THALIDOMIDE; TOSITUMOMAB I 131; VANCOMYCIN; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA; ERYTHRODERMA; FEMALE; GRAFT VERSUS HOST REACTION; HOSPITAL DISCHARGE; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN EXFOLIATION; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME; VOMITING;

COMBINED MODALITY THERAPY; FATAL OUTCOME; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA;

EID: 59549095162     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.295     Document Type: Article

References (40)

1. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
2. + T cells to elicit hepatic graft-versus-host disease. J Immunol 2002; 169: 7111-7118.
3. Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2002; 97: 2886-2895.
4. Van den Brink MR, Burakoff SJ. Cytolytic pathways in hematopoietic stem-cell transplantation. Nat Rev Immunol 2002; 2: 273-281.
5. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/ granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997; 100: 904-911.
6. Hess A, Jones R. Autologous graft vs host disease. In: Blume K, Froman SJ, Appelbaum F (eds). Thomas' Hematpoietic Cell Transplantation, 3rd edn. Blackwell Scientific Publishing: Malden, MA, 2004 pp 405-413.
7. Tzung S-P, Hackman RC, Hockenberry DM, Bensinger W, Schiffman K, McDonald GB. Lymphocytic gastritis resembling graft versus host disease following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 1998; 4: 43-48.
8. Saunders MD, Shulman HM, Murakami CS, Chauncey TR, Bensinger WI, McDonald GB et al. Bile duct apoptosis and cholestasis resembling acute graft versus host disease after autologous hematopoietic cell transplantation. Am J Surg Pathol 2000; 24: 1004-1008.
9. Hood AF, Vogelsang GB, Black LP, Farmer ER, Santos GW. Acute graft versus host disease: Development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745-750.
10. Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB et al induction of graft versus host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754-757.
11. Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Altomonte V, Hess AD et al. Induction of cutaneous graft versus host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 80: 2948-2950.
12. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K et al. Phase I trial of cyclosporine-induced autologous graft versus host disease in patients with multiple myeloma undergoing high dose chemotherapy with autologous stem cell rescue. J Clin Oncol 1997; 15: 667-673.
13. Fischer AC, Ruvolo PP, Burt R, Horwitz LR, Bright EC, Hess JM et al Characterization of the autoreactive T cell repertoire in cyclosporine-induced syngeneic graft versus host disease, a highly conserved repertoire mediates autoaggression. J Immunol 1995; 154: 3713-3725.
14. Chen W, Thoburn C, Hess AD. Characterization of the pathogenic autoreactive T cells in cyclosporine-induced syngeneic graft versus host disease. J Immunol 1998; 161: 7040-7046.
15. Hess AD, Thoburn CJ, Chen W, Horwitz LR. Complexity of effector mechanisms in cyclosporine-induced syngeneic graft versus host disease. Biol Blood Marrow Transplant 2000; 6: 13-24.
16. Hess AD, Thoburn CJ. Immune tolerance to self major histocompatibility complex class II antigens after bone marrow transplantation: Role of regulatory T cells. Biol Blood Marrow Transplant 2006; 12: 518-529.
17. Holmberg L, Kikuchi K, Gooley TA, Adams KM, Hockenberry DM, Flowers MED et al. Gastrointestinal graft versus host disease in recipients of autologous hematopoietic stem cells: Incidence, risk factors and outcome. Biol Blood Marrow Transplant 2006; 12: 226-234.
18. Piqueras B, Lavenu-Bombled C, Galicier L, Bergeron-van der Cruyssen F, Mouthon L et al. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J Clin Immunol 2003; 23: 385-400.
19. Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E et al. The EUROclass trial: De.ning subgroups in common variable immunodeficiency. Blood 2007; 111: 77-85.
20. + regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp 2003; 252: 67-88.
21. Miura Y, Thoburn CJ, Bright EC, Hess AD. Cytolytic effector mechanisms and gene expression in autologous graft versus host disease: Distinct roles of perforin and fas ligand. Biol Blood Marrow Transplant 2004; 10: 156-170.
22. Busca A, Locatelli F, Lovisone E, Ottobrelli A, Boggio D, Novero D et al. Treatment of severe refractory acute graft versus host disease of the gastrointestinal tract with Campath-1H. Biol Blood Marrow Transplant 2005; 11: 734-736.
23. Wandroo F, Auguston B, Cook M, Craddock C, Mahendra P. Successful use of Campath-1H in the treatment of steroid refractory liver GVHD. Bone Marrow Transplant 2004; 34: 285-287.
24. Carella AM, Beltrami G, Scalzulli PR, Carella Jr AM, Corsetti MT. Alemtuzumab can successfully treat steroid-refractory acute graft versus host disease. Bone Marrow Transplant 2004; 33: 131-132.
25. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N J Engl Med 2005; 352: 2487-2498.
26. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 1-6.
27. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
28. Condomines M, Quittet P, Lu Z-Y, Nadal L, Latry P, Lopez E et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high dose cyclophosphamide and granulocyte colony stimulating factor. J Immunol 2006; 176: 6631-6639.
29. Ahmad I, Haider K, Kanthan R. Autoimmune thrombocytopenia following tandem autologous peripheral blood stem cell transplantation for refractory germ cell tumor. Bone Marrow Transplant 2004; 34: 279-280.
30. Lambertenghi Deliers G, Annaloro C, Della Volpe A, Oriani A, Pozzoli E, Soligo D. Multiple autoimmune events after autologous bone marrow transplantation. Bone Marrow Transplant 1997; 19: 745-747.
31. Ishikawa F, Shigematsu H, Gondo H, Okamura T, Niho Y. Autoreactive antibodies following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 22: 729-731.
32. Isshiki I, Okamoto S, Kakimoto T, Chen CK, Mori T, Yokoyama K et al Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma. Int J Hematol 2006; 84: 354-358.
33. + T cells that survive irradiation regulate graft versus host disease. Blood 2004; 104: 1565-1573.
34. Sanchorawala V, Wright DC, Quillen K, Finn KT, Dember LM, Berk JL et al. Tandem cycles of high dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 2007; 110: 3561-3563.
35. Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin's lymphoma. Biol Blood Marrow Transplant 2007; 13: 594-600.
36. Tiersten A, Selleck M, Smith DH, Wertheim I, Kaufman E, Hershman D et al. Phase I/II study of tandem cycles of high dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer. Int J Gynecol Cancer 2006; 16: 57-64.
37. Kroger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C et al Randomized trial of single compared with tandem high dose chemotherapy followed by autologous stem cell transplantation with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol 2006; 24: 3919-3926.
38. Attal M, Harousseau J-L, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Eng J Med 2003; 349: 2495-2502.
39. Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M et al. Tandem autologous stem cell transplantation in high risk de novo multiple myeloma: Final results of the prospective and randomized ZIFM 99-04 protocol. Blood 2006; 107: 397-403.
40. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long term results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158-164.